Sex Hormone Disorder Yields Important Clues To Mechanisms Underlying Steroid Hormone Synthesis

December 20, 1996

As reported in today's issue of The New England Journal of Medicine, scientists at the University of Pennsylvania Medical Center and the University of California at San Francisco have clarified the molecular mechanisms underlying a rare disease in which genetically male newborns -- that is, infants with both X and Y chromosomes -- are born with female external genitalia due to an inability to manufacture sex hormones. The study also provides further evidence that a protein known as StAR regulates the essential first step in the biosynthesis of all steroid hormones. These hormones are used by the body to regulate the development and activity of reproductive and other organs.

"This research advances our understanding of the molecular basis of how the sex hormones that determine our sexual phenotype and the adrenal hormones that control our responses to stress are produced," says Jerome F. Strauss III, MD, PhD, a professor of obstetrics and gynecology at Penn and coauthor on the paper.

Specifically, the scientists analyzed the genetic mutations found in patients with the rare, devastating disease called congenital lipoid adrenal hyperplasia, the most severe gene-based disorder of steroid hormone synthesis. In this disease, affected people are almost completely unable to make steroid hormones because they cannot convert cholesterol to pregnenolone, the first step in the process of steroid hormone synthesis. As a result, newborns with the XY karyotype are born with female external genitalia. In addition, the adrenal cortex of these individuals becomes engorged with cholesterol. Without treatment, the absence of steroid hormones results in severe chemical imbalances, dehydration, and death during infancy.

Earlier research by the Penn and UCSF teams had localized the defect in this disorder to mutations in the gene for the steroidogenic acute regulatory (StAR) protein. In the current study, the researchers studied the mutations found in 15 patients with divergent ethnic and genetic backgrounds to see whether different mutations are associated with different levels of severity and to try to understand how the various mutations cause the disease. Among these patients, 15 different mutations were identified. They found that while the genital manifestations of the disease are fairly consistent, the physiological clinical symptoms such as dehydration, hypertension, and wasting varied considerably. The researchers concluded that congenital lipoid adrenal hyperplasia results from two separate problems: First, mutant StAR proteins block use of cholesterol to synthesize steroid hormones and, second, the resulting accumulation of cholesterol esters and related substances damages the cells.

In a related paper that appeared in the November 26 issue of the Proceedings of the National Academy of Sciences, research associate Futoshi Arakane, MD, with Strauss and colleagues, probed further into the mechanism by which StAR stimulates conversion of cholesterol to pregnenolone. Prior studies had suggested that StAR transported cholesterol across the outer and inner mitochondrial membranes. This study showed, however, that StAR itself does not need to enter into the mitochondria for cholesterol metabolism to take place.

Together, these studies confirm that StAR plays a central role in the synthesis of steroid hormones. The specific mechanism by which StAR facilitates the conversion of cholesterol to pregnenolone remains unclear and is the object of ongoing research.

-- Dr. Jerome F. Strauss III can be reached at (215) 898-0147.

The University of Pennsylvania Medical Center's sponsored research ranks fifth in the nation, based on grant support from the National Institutes of Health -- $140.5 million in federal fiscal year 1995. In addition, the institution posted the highest growth rate in its research activity -- 11.4 percent -- of the top ten academic medical centers during the same period. Penn news releases are available to reporters by direct e-mail, fax, or U.S. mail, upon request. They are also posted electronically to the NASW (National Association of Science Writers) Online and SciNews-MedNews sections of the Journalism Forum, a component of CompuServe, and to EurekAlert! (, an Internet resource sponsored by the American Association for the Advancement of Science. Additionally, they are distributed via the electronic news service Quadnet.


University of Pennsylvania School of Medicine

Related Cholesterol Articles from Brightsurf:

Cholesterol's effects on cellular membranes
The findings have far-reaching implications in the general understanding of disease, the design of drug delivery methods, and many other biological applications that require specific assumptions about the role of cholesterol in cell membranes.

Autism-cholesterol link
Study identifies genetic link between cholesterol alterations and autism.

Microbes might manage your cholesterol
Researchers discover a link between human blood cholesterol levels and a gene in the microbiome that could one day help people manage their cholesterol through diet, probiotics, or entirely new types of treatment.

Experimental cholesterol-lowering drug effective at lowering bad cholesterol, study shows
Twice-yearly injections of an experimental cholesterol-lowering drug, inclisiran, were effective at reducing low-density lipoprotein (LDL) cholesterol, often called bad cholesterol, in patients already taking the maximum dose of statin drugs, according to data of the ORION-10 trial presented Saturday, Nov.

Rethinking how cholesterol is integrated into cells
Cholesterol is best known in connection with cardiovascular disease, but cholesterol is also vital for many fundamental processes in the body.

Seed oils are best for LDL cholesterol
Using a statistical technique called network meta-analysis, researchers have combined the results of dozens of studies of dietary oils to identify those with the best effect on patients' LDL cholesterol and other blood lipids.

Cholesterol leash: Key tethering protein found to transport cellular cholesterol
Cholesterol is an essential component of living organisms, but the mechanisms that transport cholesterol inside the cell are poorly understood.

New way to treat cholesterol may be on the horizon
A breakthrough discovery by scientists at Houston Methodist Research Institute could change the way we treat cholesterol.

How low should LDL cholesterol go?
New analysis shows that in a high-risk population, achieving ultra-low LDL cholesterol levels, down to <10 mg/dL, safely results in additional lowering of risk of cardiovascular events.

Does boosting 'good' cholesterol really improve your health?
A new review addresses the mysteries behind 'good' HDL cholesterol and why boosting its levels does not necessarily provide protection from cardiovascular risk for patients.

Read More: Cholesterol News and Cholesterol Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to